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 1 
Minimal residual disease in lymph nodes after achievement of complete 1 




Most dogs with large B-cell lymphoma (LBCL) that undergo chemotherapy 6 
and achieve clinical complete remission (CR) eventually relapse. However, 7 
time to relapse (TTR) is unpredictable. The aims of this prospective study 8 
were to assess the influence of post-chemotherapy lymph node (LN) 9 
infiltration by large CD21+ cells using flow cytometry (FC) on TTR, and to 10 
establish a cut-off value of prognostic significance. 11 
Dogs with newly-diagnosed, completely staged LBCL in CR after treatment 12 
were enrolled. Minimal residual disease (MRD) analysis by FC was 13 
performed on LN aspirates. TTR was calculated between MRD and relapse. 14 
Thirty-one dogs were enrolled: 4% had stage V disease, and DLBCL was the 15 
most common histotype (74%). Based on LN infiltration at MRD evaluation, 3 16 
groups were created: 1) acellular samples; 2) ≤0.5% infiltration; and 3) >0.5% 17 
infiltration. Overall median TTR was 154 days (range, 31-1974): 22 (71%) 18 
dogs relapsed during the study period, whereas 9 (29%) dogs did not. The 19 
difference among the 3 groups was significant (p=0.042 log-rank test): 20 
median TTR was not reached for dogs with LN infiltration ≤0.5% (range, 195-21 
 2 
429 days), 164 days (range 63-1974) for dogs with acellular LN samples, and 22 
118 days (range, 31-232) for dogs with LN infiltration >0.5%.  23 
These results demonstrate that MRD assessment by FC on LN aspirates in 24 
dogs with LBCL in clinical CR predicts TTR. LN infiltration by >0.5% large 25 
CD21+ cells after treatment is an unfavorable prognostic factor. 26 
 27 
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Introduction  31 
 32 
In dogs, multicentric lymphoma is most frequently diagnosed, and in 33 
approximately 70% of cases it is of B-cell origin.1-4 Large B-cell lymphoma 34 
(LBCL) is characterized by medium or large-sized cells that express CD21 by 35 
flow cytometry (FC).5,6 36 
Despite significant improvements in terms of prognosis due to better 37 
treatments for LBCL, most dogs that undergo first-line chemotherapy and 38 
achieve clinical complete remission (CR) will ultimately relapse. The CHOP-39 
based maintenance-free chemotherapeutic protocol including Prednisolone, 40 
Vincristine, Cyclophosphamide, Doxorubicin +/- L-Asparaginase is 41 
considered to be the gold standard treatment for dogs with LBCL.7-10  42 
According to the published literature, CR rate and median first remission 43 
duration range between 80-85% and 87-330 days, respectively.8,11-17 In dogs 44 
with multicentric lymphoma the measurement of peripheral lymph nodes 45 
(LNs) size after chemotherapy is used to document treatment response.18 46 
According to the Veterinary Cooperative Oncology Group (VCOG) guidelines, 47 
clinical CR is defined as the regression of all affected peripheral LNs to a size 48 
considered normal by physical examination using LN palpation and calipers.18 49 
Following clinical remission, the residual population of tumor cells can be 50 
referred to as the minimal residual disease (MRD), which is implicated as the 51 
source of tumor relapse. Therefore, measurement of MRD can provide 52 
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information regarding the presence of neoplastic cells even in the clinical CR 53 
phase. 54 
Several techniques, including FC and polymerase chain reaction amplification 55 
of antigen receptor genes (PARR), have been used to detect MRD in LN, 56 
peripheral blood (PB) and bone marrow (BM) samples in dogs with LBCL.19,20 57 
Molecular techniques for detection of MRD in PB samples during or following 58 
treatment can be used as an objective parameter for the determination of 59 
treatment efficacy and to select dogs that might benefit from consolidation 60 
chemotherapy despite clinical CR.21-26 However, the universal primers 61 
previously designed for PARR showed a low sensitivity for MRD evaluation.19 62 
In the current study FC was tested as an alternative method for detection of 63 
MRD in the routine clinical practice. 64 
 65 
The first aim of this prospective study was to assess the influence on time to 66 
relapse (TTR) of LN infiltration by large CD21+ cells quantified by FC in dogs 67 
with LBCL in clinical CR after treatment. The second aim was to establish a 68 
cut-off value of prognostic significance. It was hypothesized that the detection 69 
and quantification of a certain amount of neoplastic cells using FC on LNs 70 
samples at the time of MRD monitoring could help predicting early relapse. 71 
 72 
 73 
Material and methods  74 
 5 
 75 
Patient selection and inclusion criteria  76 
Client-owned dogs with newly-diagnosed, previously untreated multicentric 77 
LBCL were prospectively enrolled. To be eligible for recruitment dogs were 78 
required to undergo a complete initial staging work-up (T0), consisting of 79 
history and physical examination, complete blood cell count with differential, 80 
serum biochemistry profile, thoracic radiographs, abdominal ultrasound, 81 
cytological evaluation of liver and spleen regardless of their sonographic 82 
appearance, FC on LN, PB and BM. Dogs were required to be diagnosed 83 
with LBCL based on the presence of large-sized CD21+ cells using cytology 84 
and FC. Dogs also underwent surgical removal of a peripheral LN to obtain a 85 
histopathological diagnosis.  Only dogs with a histopathological diagnosis of 86 
Diffuse Large B-cell Lymphoma (DLBCL) or Marginal Zone Lymhpoma (MZL) 87 
were enrolled in the study. All dogs received a CHOP-based dose-intense 88 
chemotherapy protocol with an autologous vaccine.27 Dogs in clinical CR 89 
following treatment based on clinical, radiological, ultrasonographic and 90 
cytological investigations were the subject of the analysis and underwent 91 
MRD assessment using FC on post-chemotherapy LNs (T1). 92 
Written informed consent was obtained from all owners.  93 
 94 
Evaluation of MRD by FC  95 
 6 
MRD evaluation by FC was performed on LN aspirates, PB and BM samples 96 
2-4 weeks after the completion of the treatment protocol if dogs were 97 
documented to be in clinical CR. Multiple peripheral LNs were aspirated; in 98 
case of non-palpable nodes, ultrasound was used as a guide.  99 
LN samples were collected into tubes containing 1 ml of RPMI 1640. PB and 100 
BM samples were collected in K3-EDTA tubes. For each matrix, a cytological 101 
specimen obtained from the same aspirate was also prepared. 102 
Samples were delivered to the laboratory and processed as previously 103 
described within 24 hours from sampling.13  104 
The cellularity of all matrices was tested with an automated haematology 105 
analyser (Sysmex XT-2000iV, Sysmex, Kobe, Japan). According to internal 106 
standard procedures, at least 1x103 nucleated cells/µl were considered 107 
necessary for the evaluation of residual disease in the LN samples (which 108 
means a total of 1x106 nucleated cells in the sample), otherwise the sample 109 
was reported as “acellular” and not further processed. 110 
Two tubes for FC were prepared for each matrix: one tube with unstained 111 
cells served as negative control. In the second tube, cells were labelled with 112 
anti-CD45-FITC (clone YKIX716.13, AbD Serotec, Oxford, UK) and anti-113 
CD21-AF647 (clone CA2.1D6, AbD Serotec) antibodies. After incubation with 114 
antibodies, PB and BM samples underwent RBC lysis by means of a solution 115 
containing 8% ammonium chloride. Tubes were finally washed and re-116 
suspended in 500µl of PBS and acquired with a BD FACScalibur flow 117 
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cytometer (Becton Dickinson, San Josè, CA). For each tube, 10,000 118 
nucleated cells were acquired. Analyses were performed with the specific 119 
software CellQuest (Becton Dickinson). A first gate was set in the 120 
morphological scattergram to exclude debris and platelets, and a second one 121 
to include only CD45-positive cells. For each matrix the residual disease was 122 
quantified based on the percentage of large-sized CD21-positive cells out of 123 
the total CD45-positive cells (Figure 1). As cut-off value, the mean FSC value 124 
of the neutrophil population (ranging between 350 and 400 based on our 125 
experimental condition) was used.   126 
 127 
Follow-up  128 
Dogs had to undergo follow-up evaluations to assess the remission status 129 
consisting of physical examination, peripheral LNs size measurement and 130 
cytological evaluation every 4 weeks during the first year, and every other 131 
month thereafter. Relapse was defined as the clinical reappearance and 132 
cytological evidence of lymphoma with or without FC confirmation in any 133 
anatomical site in dogs having experienced CR. Once relapse was confirmed, 134 
a complete restaging work-up was undertaken, and a second round of 135 
chemotherapy was offered.  136 
 137 
Statistical analysis 138 
 139 
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TTR was calculated from the assessment of MRD to relapse. Dogs lost to 140 
follow-up, dead for lymphoma-unrelated causes before relapse, or those still 141 
in CR at the end of the study, were censored for TTR analysis. 142 
In order to identify the best promising cut-off to discriminate 2 prognostic 143 
groups based on LN infiltration at MRD assessment, Kaplan-Meier curves 144 
were drawn and visually inspected. The following values were arbitrarily 145 
selected and checked to this aim: 0.5%, 1.0%, 3.0% and 5.0%.  146 
Based on data distribution, only the 0.5% cut-off was tested on PB and BM 147 
samples. 148 
Once the best cut-off was identified, a Cox’s proportional hazard regression 149 
analysis was performed, to assess the possible association of the following 150 
variables with TTR: breed (purebred or crossbred), sex (male or female), age 151 
(< or ≥ 10 years), body weight (< or ≥ 10 kg), initial stage (I to V according to 152 
WHO), substage (a or b), extranodal site involvement (yes or no), anemia 153 
(hematocrit < 35%, yes or no), thrombocytopenia (platelets <200,000/L, yes 154 
or no), serum LDH activity (< or ≥ 300 IU/L) histotype (DLBCL, MZL), LN 155 
group (acellular, ≤0.5% infiltrated, >0.5% infiltrated), residual disease in PB 156 
(%) and BM (%).For categorical variables, Kaplan Meier curves were drawn 157 
and compared with log-rank test to assess possible variations in median TTR. 158 
All statistical analyses were performed using a standard statistical software 159 




Results  163 
Demographics 164 
Thirty-one dogs met the study inclusion criteria and were enrolled. There 165 
were 7 (22.6%) crossbreed, and the remaining 24 (77.4%) represented 20 166 
different breeds. Among the purebred dogs, there were 3 (9.7%) German 167 
shepherds, 2 (6.4%) Rottweilers, 2 (6.4%) Poodles, and one (3.2%) each of 168 
the following: Dachshund, Beagle, English bulldog, Shih-tzu, Dogo Argentino, 169 
Doberman, Basset hound, Border collie, Shar Pei, Bernese Mountain dog, 170 
Boxer, German shorthaired pointer, Akita Inu, French bulldog, American 171 
staffordshire, Pomeranian, West Highland White Terrier.  172 
Eighteen (58.1%) dogs were males (4 castrated) and 13 (41.9%) were 173 
females (11 spayed). The median age at diagnosis was 7 years (range, 4-12 174 
years), whereas the median weight was 27.3 kg (range, 3.9-59.7 kg). 175 
 176 
Clinico-pathological features 177 
Two (6.5%) dogs were anemic, and 7 (22.6%) were thrombocytopenic. LDH 178 
activity was increased in 7 (23.3%) dogs (300 IU/L) out of 30 dogs tested, 179 
whereas serum ionized calcium was within normal limits in all cases.  180 
Four (12.9%) dogs had stage III (substage a) disease, 14 (45.2%) had stage 181 
IV (substage a) disease, and 13 (41.9%) had stage V disease (n=8 substage 182 
 10 
a, and n=5 substage b). In 2 (6.5%) cases, extranodal (pulmonary) sites were 183 
involved.  184 
There were 23 (74.2%) DLBCL and 8 (25.8%) MZL. 185 
 186 
MRD assessment on LN, PB and BM 187 
At the time of MRD assessment, all dogs were in clinical CR. A LN aspirate 188 
was obtained in all of them and submitted for FC analysis. The aspirates 189 
obtained from 13 (41.9%) dogs were acellular. Among the 18 processed 190 
samples, median infiltration by large CD21+ cells was 1.3% (mean 191 
5.7±13.0%; min-max 0.3-53.5%). In particular, it was 0.5% in 3 (9.7%) 192 
cases, 1.0% in 7 (22.6%), 3.0% in 13 (41.9%), and 5.0% in 15 (48.4%) 193 
dogs.  194 
PB was tested for MRD by FC in all 31 cases. Median infiltration was 0.3% 195 
(mean 0.41±0.34%; min-max 0.1-1.5%). In particular, it was 0.5% in 21 196 
(67.7%) dogs.  197 
BM was tested for MRD by FC in 25 (80.6%) cases. Median infiltration was 198 
0.3% (mean 0.51±0.49%; min-max 0.1-1.9%). In particular, it was 0.5% in 199 
16 (64%) dogs.  200 
 201 
Outcome and prognostic groups based on LN infiltration 202 
Overall median TTR was 154 days (range 31-1974 days). Twenty-two (71%) 203 
dogs relapsed during the study period, whereas 9 (29%) were censored for 204 
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TTR (8 were still alive and in CR at data analysis closure and 1 died from 205 
unrelated causes still being in CR for lymphoma after 61 days). 206 
Among the 4 cut-offs tested for LN infiltration, only 0.5% discriminated among 207 
prognostic groups (Figure 2). Thus, three groups were created for statistical 208 
analysis, based on LN infiltration at MRD assessment: 1) acellular LN 209 
sample; 2) 0.5% infiltration; and 3) 0.5% infiltration. Conversely, no 210 
discriminating cut-off was identified for PB and BM samples. 211 
The three LN groups significantly differed for median TTR according to log-212 
rank test (p=0.042), but not according to Cox analysis (p=0.067). 213 
Nevertheless, significant results were obtained with Cox analysis when LN 214 
groups 1 and 2 were coupled together and compared with samples >0.5% 215 
infiltration (p=0.030, Figure 3). None of the remaining variables significantly 216 
influenced TTR by either test. Median TTR and p-values for all variables are 217 
listed in Table 1. 218 
 219 
 220 
Discussion  221 
 222 
Monitoring MRD is crucial for dogs with LBCL undergoing treatment. Relapse 223 
is the major cause of treatment failure and decrease in survival rate, and it 224 
emerges from the outgrowth of residual treatment-resistant neoplastic cells.28 225 
While diagnosing an overt relapse is quite straightforward, recognizing the 226 
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presence of residual neoplastic cells if peripheral LNs are not enlarged is 227 
challenging. The current prospective study shows that MRD assessment by 228 
FC on LN samples in dogs with LBCL in clinical CR may predict TTR, thereby 229 
representing a useful tool for disease monitoring after therapy completion. In 230 
detail, dogs with 0.5% LN infiltration were more likely to relapse despite the 231 
clinical CR.  232 
According to the VCOG guidelines, all dogs in the present study were in 233 
clinical CR at the end of treatment18, yet 50% of them had detectable MRD 234 
based on FC, ultimately leading to early relapse. Thus, FC may play a role 235 
not only in the initial diagnostic work up5,6,13,29,30, but also in post-treatment 236 
surveillance. In fact, cytology and even imaging may occasionally detect 237 
clinically occult relapse, but the benefit of these techniques has not been 238 
demonstrated in LBCL. Whether the detection of relapse ahead of clinical 239 
symptoms translates into a clinical benefit was not investigated in the current 240 
study, therefore it is currently unknown whether early MRD-based 241 
intervention can affect outcome. Nevertheless, these results allow at least the 242 
question to be addressed in clinical trials, by including MRD assessment at 243 
the end of treatment to document the presence or absence of subclinical 244 
disease. 245 
 246 
The second aim of this study was to establish a cut-off value of prognostic 247 
significance for TTR. The identification of a MRD cut-off value might 248 
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represent an objective and repeatable tool for risk assessment, by identifying 249 
those dogs that are at risk of relapse, yet clinically in remission phase.  250 
In the current study 22 (71%) dogs relapsed during the study at different time 251 
points (31-1974 days). By applying a cut-off value of 0.5%, two prognostic 252 
groups were identified: an early relapse group (median TTR 118 days) and a 253 
late relapse group (median TTR not reached).  254 
Because dogs with MRD >0.5% at the end of treatment had the shortest TTR, 255 
it was hypothesized that MRD could not only represent the best indicator for 256 
the risk of relapse, but also a substantial aid to decide the interval at which 257 
dogs should be monitored, possibly leading to treatment intensification.  258 
The period between clinical remission and clinical relapse was different in 259 
dogs in the early relapse group. The clinical relapse occurred after a median 260 
interval of 118 days of MRD assessment. This period was even shorter in 261 
some dogs, thereby indicating that the evolution of disease is not completely 262 
similar in all dogs despite being categorized in the same risk group. 263 
Based on the above, we strongly recommend to assess the clinical remission 264 
status on a biweekly basis if MRD is above the defined threshold, as a follow-265 
up interval of 2 weeks allows predicting the clinical relapse events before 266 
clinical manifestations. 267 
 268 
Conversely, dogs with MRD levels 0.5% or those in which LN samples were 269 
acellular were mostly associated with a good outcome. While the threshold of 270 
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0.5% is intuitive, one may argue the meaning of acellular samples. 271 
In the current study, at least 1x106 intact cells (1x103 nucleated cells/µl) 272 
were considered necessary for the evaluation of MRD by FC. This threshold 273 
was arbitrarily set, since this amount of cells is required for the application of 274 
a minimal immunophenotyping panel according to internal standard 275 
procedures. Indeed, working dilutions of the antibodies have been 276 
established for a concentration of 500,000 cells/tubes. While the reduced 277 
panel of antibodies used here may be adapted to less cellular samples, thus 278 
possibly reducing the percentage of “acellular” cases, it must be noted that 279 
statistically the acellular samples tended to overlap with those with <0.5% 280 
infiltration in terms of outcome. The most likely explanation for this finding is 281 
that dogs achieving CR after treatment undergo LNs atrophy, as previously 282 
documented.19 Fine-needle aspirates obtained from one or more peripheral 283 
LNs were always evaluated by means of cytology prior to FC analysis, to 284 
ensure that a LN was actually sampled. Despite having performed 285 
ultrasound-guided fine-needle aspiration of multiple peripheral non-palpable 286 
LNs and having obtained good cytological smears (data not shown), the 287 
cellularity of atrophic LNs was inadequate for flow cytometric analysis in 13 288 
dogs, yielding acellular samples. Nevertheless, dogs with acellular samples 289 
at the end of treatment experienced a long TTR. Based on the above, 290 
acellular samples by FC suggest that residual neoplastic cells are virtually 291 
absent in the LNs, ultimately being associated to a good prognosis.  292 
 15 
 293 
This study has some limitations.  294 
While cytology and FC are commonly used for diagnosing canine lymphoma, 295 
histopathology is still not routinely performed. Despite the group enrolled in 296 
the current study was homogeneous as far as cytological and FC features, 297 
histopathology showed that there were 23 aggressive (DLBCL) and 8 indolent 298 
lymphomas (MZL). Further development and validation of MRD techniques 299 
are required to confirm that FC detection of residual neoplastic cells is 300 
feasible and prognostic among all lymphoma subtypes. Also, dogs underwent 301 
one single MRD testing 2-4 weeks after the end of treatment. This time point 302 
was arbitrarily selected. It is possible that MRD assessment at different time 303 
points or incorporated in serial monitoring could add value for clinical 304 
management.  305 
MRD testing itself has some technical and practical limitations, as a 306 
significant number of MRD-negative dogs still relapse. First, while the 307 
cellularity of samples is crucial for FC analysis, the minimal amount of 308 
neoplastic cells that permits sample processing has not been clearly 309 
identified. Second, clonality of putative neoplastic cells cannot be tested by 310 
FC. We assessed the percentage of large CD21+ cells in LNs after treatment 311 
because these cells have the same FC morphological and immunophenotypic 312 
features of neoplastic cells at diagnosis. Still, medium or large reactive B-313 
cells may have been included in the count, thereby falsely increasing MRD 314 
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values. Finally, it would be interesting to evaluate if LN aspirates from 315 
different sites may influence the percentage of infiltration thus causing 316 
migration from one relapse group to another. All these aspects could be 317 
better elucidated in specific studies aimed to create standardized 318 
recommendation for the assessment of MRD via FC in dogs with LBCL.   319 
 320 
In conclusion, the present study indicates that MRD assessment by FC on LN 321 
aspirates is a useful tool for assessing the presence of subclinical disease in 322 
dogs with LBCL treated with chemo-immunotherapy. Relapse occurrence 323 
could be efficiently predicted through FC prior to clinical relapse diagnosis, 324 
and the value >0.5% was associated with early recurrence. Further trials 325 
randomizing dogs according to their MRD-status are required to assess 326 
whether MRD-guided management of dogs with LBCL will ultimately lead to 327 
improved outcome and personalized care. 328 
 329 
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Table 1: Time To Relapse (TTR) in 31 dogs with large B-cell lymphoma 438 
(LBCL), according to different variables 439 
Variables (number of 
dogs) 







- purebred (24) 







- male (18) 






- <10 years (19) 






- <10 kg (5) 






- III (4) 
- IV (14) 








- a (26) 







- yes (2) 







- yes (2) 






- yes (7) 





Serum LDH activity 
- normal (23) 






- DLBCL (23) 





Residual disease in 
lymph nodes 






- >0.5% (15) 





Residual disease in 
peripheral blood (%) 
(31) 
 0.608  
Residual disease in 
bone marrow (%) (25) 
 0.392  
 440 
Figure 1 441 
Flow cytometric scattergrams showing Minimal Residual Disease (MRD) 442 
evaluation in 3 dogs with Large B-Cell Lymphoma (LBCL). Left column: a first 443 
gate in a morphological scattergram was set to exclude platelet and debris 444 
(R1). Central column: only R1 events are shown; a second gate was set to 445 
include only CD45-positive events. Right column: only events included in both 446 
R1 and R2 are shown; MRD was calculated as the percentage of cells in the 447 
upper right quadrant (large-sized CD21-positive cells). The three rows show 3 448 
cases with different MRD levels. 449 
 450 
 451 
Figure 2 452 
 25 
Kaplan-Meier curves showing Time To Relapse (TTR) in 31 dogs with large 453 
B-cell lymphoma (LBCL) according to flow cytometric (FC) results on post-454 
chemotherapy lymph node (LN) aspirates, peripheral blood (PB) and bone 455 
marrow (BM) samples. Dashed line: large CD21+ cells ≤ the cut-off. 456 
Continuous line: large CD21+ cells > the cut-off. Dotted line: acellular 457 
samples. A-D: cases were classified according to percentage of residual 458 
disease in LN aspirates. A: the cut-off was set at 0.5%. B: the cut-off was set 459 
at 1.0%. C: the cut-off was set at 3.0%. D: the cut-off was set at 5.0%. E: 460 
cases were classified according to the percentage of residual disease in PB 461 
samples; the cut-off was set at 0.5%. F: cases were classified according to 462 
the percentage of residual disease in BM samples; the cut-off was set at 463 
0.5%. 464 
 465 
Figure 3 466 
Kaplan-Meier curves showing Time To Relapse (TTR) in 31 dogs with large 467 
B-cell lymphoma (LBCL) according to flow cytometric (FC) results on post-468 
chemotherapy lymph node (LN) aspirates. Continuous line: large CD21+ cells 469 
> 0.5%. Dotted line: large CD21+ cells ≤ 0.5% and acellular samples. The 470 
difference between the two groups was statistically significant (p=0.030). 471 
 472 
 473 
 474 
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